Fig. 5
From: Several first-line anti-hypertensives act on fibrosarcoma progression and PD1ab blockade therapy
Spironolactone did not affect fibrosarcoma growth but weakened tumor immune responses to PD1ab. A CCK8 experiment was used to detect the proliferation ability of MCA-205 after of spironolactone treatment. B Elisa kit was used to detect the VEGF production after spironolactone treatment. C A double therapy (spironolactone and PD1ab) or monotherapies (spironolactone or PD1ab) were used for curing MCA-205-neoplasms mice. D–F Tumor mass (D) and weight (E) from MCA-205-neoplasms mice (n = 10) were demonstrated. F Survival of mice (n = 10) was monitored biweekly after treatment. G–H The number of CD8+ T cells infiltration after treatment. Scale bars, 20 μm